Waystar Mulls Sale Amid Software Sector Slump, Sources Reveal

Waystar, a prominent healthcare software provider known for its payment management solutions, is reportedly exploring a range of strategic options, including a possible sale. This development comes two years after the company's public listing on the New York Stock Exchange. According to seven individuals familiar with the situation, Waystar has enlisted the services of investment bank Evercore to guide the process, which remains in its initial stages.

The Lehi, Utah, and Louisville, Kentucky-based company, which emerged from the 2017 merger of Zirmed and Navicure, aims to reposition itself as a technology-focused entity. By automating and managing administrative tasks, Waystar seeks to achieve higher valuations typical of tech firms, rather than being perceived as a traditional healthcare services company reliant on human labor.

Market Value Decline Spurs Strategic Review

Waystar's market capitalization has dwindled to approximately $4.8 billion following a 24% drop in its share price this year, amid a widespread downturn in the software sector. This has prompted the company to evaluate its strategic options, with a potential auction process intended to assess investor interest in software assets.

Despite initial investor enthusiasm, which saw Waystar's share price climb from $20 to a peak of $45 in 2025, concerns over the impact of artificial intelligence on the software industry have contributed to recent declines. Analysts from Morgan Stanley highlighted these apprehensions in a July report.

Key Stakeholders and Financial Backers

Waystar's major shareholders include private equity firm EQT, the Canada Pension Plan Investment Board (CPPIB), and BlackRock Institutional Trust Company. EQT holds a 13% stake, while CPPIB and BlackRock own 10% and 8%, respectively. Notably, EQT, which played a crucial role in Waystar's 2024 public offering, remains its largest shareholder.

Neither Waystar nor Evercore have commented on the potential sale. Similarly, EQT, CPPIB, and BlackRock have refrained from providing statements regarding the ongoing process.

Potential Outcomes and Market Implications

While the exploration of a sale is underway, sources caution that plans could change, and a transaction may not ultimately occur. Nonetheless, the move highlights the challenges faced by software companies in a volatile market environment, where technological advancements and investor sentiment continue to shape business strategies.

As Waystar navigates these strategic considerations, the outcome of this process could have broader implications for the valuation and trajectory of healthcare software firms in the current economic climate.